Pharmaceutical

Oncolytics targets accelerated approval for oncolytic virus therapy

The company intends to start a registrational Phase II trial of pelareorep and chemotherapy combination for breast cancer in 2025.

Oct 8, 2024 - 04:00
Oncolytics targets accelerated approval for oncolytic virus therapy
The company intends to start a registrational Phase II trial of pelareorep and chemotherapy combination for breast cancer in 2025.
Read the original article

Tags:

Previous Article

EMA starts review into hair loss drugs about potential link to suicidal thoughts 

Next Article

Activist investor Starboard forges $1bn stake in Pfizer to swing profits

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

EC grants approval to Pfizer for $43bn Seagen acquisition 

EC grants approval to Pfizer for $43bn Seagen acquisition 

Oct 21, 2023

STAT+: Pharmalittle: U.S. pharma layoffs continue to climb; senators push insulin makers for details of low-cost programs

STAT+: Pharmalittle: U.S. pharma layoffs continue to cl...

Aug 31, 2023

Emergency medicine is grappling with a surprising problem: The prospect of too many physicians

Emergency medicine is grappling with a surprising probl...

Oct 28, 2023